An Open-Label, Multicenter, Single Arm QT Interval Prolongation Study of Eribulin Mesylate (E7389) in Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 12 Apr 2012
At a glance
- Drugs Eribulin (Primary)
- Indications Solid tumours
- Focus Pharmacodynamics
- Sponsors Eisai Inc
- 12 Apr 2012 Actual patient number is 26 according to ClinicalTrials.gov.
- 30 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 May 2010 New trial record